Effects of preserved and unpreserved low dose topical atropine eye drops on the ocular surface

Phase 4

Recruiting

• Conditions: Myopia; Dry Eye; Ocular Surface Disease; Eye - Diseases / disorders of the eye

• Registration Number: ACTRN12617000571370
• Lead Sponsor: SW Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-04-24
• Last Update Posted: 16 February 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1) Adults aged between 18-40
2) Informed consent received
3) Have normal eye and general health
4) No reported allergy to atropine or preservatives
5) Willingness to comply with scheduled visits and other study procedures
6) No history of narrow-angle glaucoma or risk of glaucoma

Exclusion Criteria

1) Atropine eye drop use prior to enrollment
2) Any ocular disease including inflammation or allergy
3) History of allergic reaction to any topical ophthalmic drugs
4) Contact lens wearer
5) Currently using topical ophthalmic drugs
6) Anyone who is taking any form of medication
7) Pregnant women, planning to become pregnant, or breast-feeding

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in non-invasive tear breakup time (NITBUT) measured by Oculus Keratograph 5M[At baseline, 1 hour after drop instillation, 3-5 hours after drop instillation, 8 days after treatment initiation and 28 days after treatment initiation]